Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, Tsuji A
Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
J Pharmacol Exp Ther. 2000 Oct;295(1):146-52.
Transport of new quinolone antibacterial agents (quinolones) at the blood-brain barrier (BBB) was studied in vitro by using immortalized rat brain capillary endothelial cells RBEC1, and in vivo by using the brain perfusion method in rats and multidrug-resistant mdr1a/1b gene-deficient mice. The permeability coefficient of grepafloxacin measured by brain perfusion was increased by an excess of unlabeled grepafloxacin, suggesting a participation of a saturable BBB efflux system. Uptake coefficients of [(14)C]grepafloxacin, [(14)C]sparfloxacin, and [(14)C]levofloxacin by RBEC1 cells at the steady state were increased in the presence of the unlabeled quinolones. The steady-state uptake of [(14)C]grepafloxacin was increased in the presence of various quinolones. Brain distributions of [(14)C]grepafloxacin and [(14)C]sparfloxacin evaluated in terms of the brain-to-plasma free concentration ratio in mdr1a/1b gene-deficient mice were significantly higher than those in wild-type mice, demonstrating an involvement of P-glycoprotein as the efflux transporter. Anionic compounds, including 4, 4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) and genistein, increased the steady-state uptake of [(14)C]grepafloxacin by RBEC1 cells. Because [(14)C]grepafloxacin was transported by multidrug resistance-associated protein (MRP), in MRP1-overexpressing cells and because RBEC1 and primary cultured brain capillary endothelial cells expressed MRP1, this protein may be an additional efflux transporter for quinolones. Furthermore, the permeability coefficient of [(14)C]grepafloxacin across the BBB was increased by DIDS or in the absence of bicarbonate ions in the brain perfusion method. DIDS or bicarbonate ion did not affect MRP1 function. Accordingly, the brain distribution of quinolones is restricted by the action of multiple efflux transporters, including P-glycoprotein, MRP1, and an unknown anion exchange transporter.
利用永生化大鼠脑微血管内皮细胞RBEC1在体外研究了新型喹诺酮类抗菌剂(喹诺酮)在血脑屏障(BBB)处的转运,并通过大鼠脑灌注法以及多药耐药mdr1a/1b基因缺陷小鼠在体内进行了研究。脑灌注法测得的格帕沙星渗透系数因未标记的格帕沙星过量而增加,提示存在可饱和的血脑屏障外排系统参与其中。在未标记喹诺酮存在的情况下,RBEC1细胞对[(14)C]格帕沙星、[(14)C]司帕沙星和[(14)C]左氧氟沙星的稳态摄取系数增加。在各种喹诺酮存在的情况下,[(14)C]格帕沙星的稳态摄取增加。在mdr1a/1b基因缺陷小鼠中,根据脑与血浆游离浓度比评估的[(14)C]格帕沙星和[(14)C]司帕沙星的脑分布显著高于野生型小鼠,表明P-糖蛋白作为外排转运体参与其中。包括4,4'-二异硫氰酸根合芪-2,2'-二磺酸(DIDS)和染料木黄酮在内的阴离子化合物增加了RBEC1细胞对[(14)C]格帕沙星的稳态摄取。由于[(14)C]格帕沙星在MRP1过表达细胞中由多药耐药相关蛋白(MRP)转运,且RBEC1和原代培养的脑微血管内皮细胞表达MRP1,因此该蛋白可能是喹诺酮类药物的另一种外排转运体。此外,在脑灌注法中,DIDS或在无碳酸氢根离子的情况下,[(14)C]格帕沙星跨血脑屏障的渗透系数增加。DIDS或碳酸氢根离子不影响MRP1功能。因此,喹诺酮类药物的脑分布受到多种外排转运体的作用限制,包括P-糖蛋白、MRP1和一种未知的阴离子交换转运体。